T
TIZIANA LIFE SCIENCES LTD
NASDAQ: TLSA (Tiziana Life Sciences Ltd)
Kemas kini terakhir: 17 jam lalu1.55
0.13 (9.15%)
| Penutupan Terdahulu | 1.42 |
| Buka | 1.52 |
| Jumlah Dagangan | 1,049,190 |
| Purata Dagangan (3B) | 392,444 |
| Modal Pasaran | 181,114,400 |
| Harga / Buku (P/B) | 42.16 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Jun 2025 - 8 Jul 2025 |
| EPS Cair (TTM) | -0.110 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.69% |
| Nisbah Semasa (MRQ) | 1.02 |
| Aliran Tunai Operasi (OCF TTM) | -1.53 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.99 M |
| Pulangan Atas Aset (ROA TTM) | -84.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -250.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Tiziana Life Sciences Ltd | Bercampur | Bercampur |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.38 |
|
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 37.72% |
| % Dimiliki oleh Institusi | 2.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Dauntless Investment Group, Llc | 31 Mar 2025 | 1,739,574 |
| Zhang Financial Llc | 31 Mar 2025 | 96,260 |
| Kovitz Investment Group Partners, Llc | 31 Mar 2025 | 79,365 |
| Bison Wealth, Llc | 31 Dec 2024 | 42,795 |
| Bison Wealth, Llc | 31 Mar 2025 | 42,795 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |